"Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFRtumours (TAILOR): a randomised controlled trial"
Lancet Jul 22
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70310-3/fulltext 
"Interpretation

Our results show that chemotherapy is more effective than erlotinib for second-line treatment for previously treated patients with NSCLC who have wild-type EGFR tumours."